Portal de Periódicos da CAPES

Platelet growth factors: potential impact on transfusion medicine

1999; Wiley; Volume: 39; Issue: 3 Linguagem: Inglês

10.1046/j.1537-2995.1999.39399219292.x

1537-2995

David J. Kuter, Jonathan Cebon, Laurence A. Harker, Lawrence D. Petz, Jeffrey McCullough,

Blood disorders and treatments

TransfusionVolume 39, Issue 3 p. 321-332 Platelet growth factors: potential impact on transfusion medicine David J. Kuter MD, DPhil, Corresponding Author David J. Kuter MD, DPhil Director of Clinical Hematology Cox 640, Massachusetts General Hospital, 100 Blossom Street, Boston, MA 02114. Disclosure: An author (DJK) has served as a consultant to companies that develop platelet growth factors and another author (JC) has received financial assistance from Amgen for laboratory services relating to the pharmacokinetics of PEG–rHuMGDF.Cox 640, Massachusetts General Hospital, 100 Blossom Street, Boston, MA 02114.Search for more papers by this authorJonathon Cebon PhD, FRACP, Jonathon Cebon PhD, FRACP Director Ludwig Institute Oncology Unit, Austin and Repatriation Medical Centre, Heidelberg, Australia.Search for more papers by this authorLaurence A. Harker MD, Laurence A. Harker MD Director Division of Hematology - Oncology, Emory University, Atlanta, GA.Search for more papers by this authorLawrence D. Petz MD, Lawrence D. Petz MD Professor of Pathology and Laboratory Medicine and Director of Transfusion Medicine, UCLA Medical Center, Los Angeles, CA.Search for more papers by this authorJeffrey McCullough MD, Jeffrey McCullough MD Director of Laboratory Medicine, University of Minnesota, Minneapolis, MN.Search for more papers by this author David J. Kuter MD, DPhil, Corresponding Author David J. Kuter MD, DPhil Director of Clinical Hematology Cox 640, Massachusetts General Hospital, 100 Blossom Street, Boston, MA 02114. Disclosure: An author (DJK) has served as a consultant to companies that develop platelet growth factors and another author (JC) has received financial assistance from Amgen for laboratory services relating to the pharmacokinetics of PEG–rHuMGDF.Cox 640, Massachusetts General Hospital, 100 Blossom Street, Boston, MA 02114.Search for more papers by this authorJonathon Cebon PhD, FRACP, Jonathon Cebon PhD, FRACP Director Ludwig Institute Oncology Unit, Austin and Repatriation Medical Centre, Heidelberg, Australia.Search for more papers by this authorLaurence A. Harker MD, Laurence A. Harker MD Director Division of Hematology - Oncology, Emory University, Atlanta, GA.Search for more papers by this authorLawrence D. Petz MD, Lawrence D. Petz MD Professor of Pathology and Laboratory Medicine and Director of Transfusion Medicine, UCLA Medical Center, Los Angeles, CA.Search for more papers by this authorJeffrey McCullough MD, Jeffrey McCullough MD Director of Laboratory Medicine, University of Minnesota, Minneapolis, MN.Search for more papers by this author First published: 19 December 2002 https://doi.org/10.1046/j.1537-2995.1999.39399219292.xCitations: 22 Supported in part by grant no. HL54838 from the National Institutes of Health (DJK) and by Amgen Inc. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Citing Literature Volume39, Issue3March 1999Pages 321-332 RelatedInformation